FindTrial
Sign In

SHR-2173 injection

DRUG6 trials

Sponsors

Guangdong Hengrui Pharmaceutical Co., Ltd

Conditions

Active Lupus NephritisGeneralized Myasthenia GravisImmune ThrombocytopeniaPrimary IgA NephropathyPrimary Membranous NephropathySystemic Lupus Erythematosus

Phase 1

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
RecruitingNCT07206758
Guangdong Hengrui Pharmaceutical Co., LtdImmune Thrombocytopenia
Start: 2025-11-12End: 2026-11-01Target: 10Updated: 2026-05-28

Phase 2

A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis
RecruitingNCT07229742
Guangdong Hengrui Pharmaceutical Co., LtdActive Lupus Nephritis
Start: 2025-11-22End: 2028-03-31Target: 51Updated: 2025-12-01
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
RecruitingNCT07289763
Guangdong Hengrui Pharmaceutical Co., LtdPrimary Membranous Nephropathy
Start: 2025-12-31End: 2027-09-01Target: 75Updated: 2026-01-26
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
RecruitingNCT07299422
Guangdong Hengrui Pharmaceutical Co., LtdSystemic Lupus Erythematosus
Start: 2026-04-03End: 2028-11-01Target: 248Updated: 2026-05-11
A Study of SHR-2173 in Participants With Primary IgA Nephropathy
RecruitingNCT07354932
Guangdong Hengrui Pharmaceutical Co., LtdPrimary IgA Nephropathy
Start: 2026-03-09End: 2027-12-01Target: 84Updated: 2026-05-13
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
Not yet recruitingNCT07622342
Guangdong Hengrui Pharmaceutical Co., LtdGeneralized Myasthenia Gravis
Start: 2026-06-01End: 2027-12-01Target: 60Updated: 2026-06-03